Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs? - sprookjes - yvandenbroek - TriplyDB

Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?

Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?

http://www.wikidata.org/entity/Q34018867

about

Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence Internet-delivered treatment for substance abuse: a multisite randomized controlled trial Reductions in anxiety and depression symptoms in youth receiving substance use treatment.Use of sexual risk assessment and feedback at intake to promote counselor awareness of subsequent client risk behavior during early treatment.Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders Relation of study design to recruitment and retention in CTN trials.The Appalachian Tri-State Node Experiences with the National Institute on Drug Abuse Clinical Trials Network.The design and analysis of multisite effectiveness trials: a decade of progress in the National Drug Abuse Clinical Trials Network Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future How practice and science are balanced and blended in the NIDA Clinical Trials Network: the bidirectional process in the development of the STAGE-12 protocol as an example.Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network Modeling site effects in the design and analysis of multi-site trials An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder Characteristics of an outpatient treatment sample by primary substance of abuse.The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients.NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

P2860

Q33783250-352E4EC6-5A41-4FC3-874D-CE51820EF6CF Q33836976-0AA6D9D6-A9D6-46D8-A1C1-493D428884F2 Q33922014-DD62BCCF-8904-41D0-BF7A-D120794A7A89 Q34133421-9512F890-AD07-4F26-924D-FC4D2F9DBBD3 Q35189691-8C78489C-B7ED-41C7-ACB2-633D4309E34A Q35215651-F5B68AD5-0641-4972-A66A-22D2F0F8F1E0 Q35552994-A58B8F3B-5464-4D26-8F7A-86B71C21CC6C Q35597594-A38249F8-CE13-4FC6-9D31-0088997F62BE Q35598143-F931EA4B-686B-4D98-B0D6-0F7571DA5433 Q35679295-3E38E9C6-9789-45DF-A769-4363FE1BB3A3 Q35714087-855A07BA-9B46-4F3D-BF80-10243DD28298 Q35762622-4CDD8DB4-54CA-48A7-BE2A-2AD82B20AA3A Q36433737-ACA091FF-30BC-4334-9B21-D7144523FF0A Q37214182-7D156622-9D5A-4948-B81C-3B39CCD81595 Q38791854-2CB00582-FF6B-4926-81EF-53057B702790 Q42289728-2F20EBA0-38A6-47AB-AAE8-A7094EF7CF27

P2860

Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?

http://www.wikidata.org/entity/Q34018867

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Multisite effectiveness trials ...... ve we chosen the best designs?

@ast

Multisite effectiveness trials ...... ve we chosen the best designs?

@en

Multisite effectiveness trials ...... ve we chosen the best designs?

@nl

type

label

Multisite effectiveness trials ...... ve we chosen the best designs?

@ast

Multisite effectiveness trials ...... ve we chosen the best designs?

@en

Multisite effectiveness trials ...... ve we chosen the best designs?

@nl

prefLabel

Multisite effectiveness trials ...... ve we chosen the best designs?

@ast

Multisite effectiveness trials ...... ve we chosen the best designs?

@en

Multisite effectiveness trials ...... ve we chosen the best designs?

@nl

P1433

Q34018867-B837D693-F838-4B05-8BDD-6BD60C5C5251

P1476

Q34018867-9C176C81-45B1-4424-B441-32EB44D81D8A

P2093

Q34018867-00A37EA1-5875-4281-8587-80B915CFD0E0

Q34018867-077BA938-AA90-4A0F-8720-5866D42C9F37

Q34018867-08163FB8-4811-403E-939C-46D7C334706C

Q34018867-1820571E-C6C7-4BDB-B359-3F11E3896B82

Q34018867-1D37774E-A09B-4497-A883-6F3837EAC768

Q34018867-26F4AC9D-12FC-4F82-92B0-4DE82D788587

Q34018867-3E773DAF-1914-4E4D-8A2C-05CD3A1BFA91

Q34018867-42D680B6-3823-4024-8F80-3E4F19A28071

Q34018867-5C930C76-BC21-4372-912A-9F9A8B795C5E

Q34018867-6BE3DE60-5557-4D9B-9D9C-57FF6835C0BD

P2860

Q34018867-0DA1F87F-B8AF-4A02-AA54-40F6EC789BFB

Q34018867-13B38CB1-1A5E-4B12-B3E7-8E93D67C77E1

Q34018867-15D3BA81-10DB-4AAC-AC86-DD522D21AA30

Q34018867-232241AC-0F0F-4397-B1AA-DD574FBAEFA0

Q34018867-30169FD0-9F40-4239-A910-B9D6A69622B1

Q34018867-3957613E-EC0E-4EA1-8BC0-98DDCC73562F

Q34018867-3F2643B3-20A7-4E51-A592-63784A6641A3

Q34018867-46D6B05D-42D3-4244-9326-9A85C80B66A3

Q34018867-4A7400D2-097B-4C3B-A587-0F42F5D6907B

Q34018867-4F9FE5A6-C2A1-40E6-B27A-2620BC389526

P304

Q34018867-1ABC79F4-C8EF-4E2E-9370-EF31F4104E91

P31

Q34018867-E7DFE7AC-7F0E-4D8F-B1BB-7CACF7AB1752

P356

Q34018867-2FD391C1-FAFE-4389-BB1F-D7AD813D01A5

P478

Q34018867-F2AEBBD8-EF37-401F-B81A-3AC109D2796C

P50

Q34018867-738096BC-FB4D-47BA-A4D0-474721989FDA

Q34018867-78C4E6AD-5DEE-469C-AB86-B44E3EFD6C52

P577

Q34018867-DC33DE82-9477-4EC5-B719-16966EB2DC3D

P5875

Q34018867-E4CC2EC4-27E8-46BF-B1AE-C21B78C6AC69

P698

Q34018867-02BE9B4C-04D9-435A-B87C-B15ADD532825

P932

Q34018867-1BB9724B-CD70-4917-875D-09797412D6EB

P356

J.JSAT.2010.01.012

P1433

Journal of Substance Abuse Treatment

P1476

Multisite effectiveness trials ...... ve we chosen the best designs?

@en

P2093

Daniel J Feaster

http://www.w3.org/2001/XMLSchema#string

Denise Hien

http://www.w3.org/2001/XMLSchema#string

Donald A Calsyn

http://www.w3.org/2001/XMLSchema#string

Edward V Nunes

http://www.w3.org/2001/XMLSchema#string

George Woody

http://www.w3.org/2001/XMLSchema#string

Gregory Brigham

http://www.w3.org/2001/XMLSchema#string

Jeffrey Selzer

http://www.w3.org/2001/XMLSchema#string

John Rotrosen

http://www.w3.org/2001/XMLSchema#string

Kathleen Carroll

http://www.w3.org/2001/XMLSchema#string

Nancy M Petry

http://www.w3.org/2001/XMLSchema#string

P2860

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network

Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions

Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.

A comprehensive guide to the application of contingency management procedures in clinical settings.

15-month followup of women methadone patients taught skills to reduce heterosexual HIV transmission.

Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.

Clinic variation in the cost-effectiveness of contingency management

Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs.

Statistical issues in multisite effectiveness trials: the case of brief strategic family therapy for adolescent drug abuse treatment.

Buprenorphine tapering schedule and illicit opioid use.

P304

S97-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JSAT.2010.01.012

http://www.w3.org/2001/XMLSchema#string

P478

38 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Theresa Winhusen

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42388829

http://www.w3.org/2001/XMLSchema#string

P698

20307801

http://www.w3.org/2001/XMLSchema#string

P932

2909698

http://www.w3.org/2001/XMLSchema#string